Lorna Moore
Concepts (452)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 87 | 2026 | 471 | 13.750 |
Why?
| | Uterine Artery | 17 | 2024 | 74 | 5.450 |
Why?
| | Fetal Growth Retardation | 35 | 2025 | 594 | 5.200 |
Why?
| | Pre-Eclampsia | 18 | 2025 | 206 | 4.500 |
Why?
| | Hypoxia | 41 | 2026 | 1209 | 4.350 |
Why?
| | Fetal Hypoxia | 12 | 2024 | 56 | 3.770 |
Why?
| | Pregnancy | 80 | 2026 | 7276 | 3.310 |
Why?
| | Acclimatization | 20 | 2019 | 170 | 3.030 |
Why?
| | Uterus | 15 | 2020 | 228 | 3.000 |
Why?
| | Placenta | 19 | 2026 | 794 | 2.870 |
Why?
| | AMP-Activated Protein Kinases | 8 | 2025 | 192 | 2.700 |
Why?
| | Altitude Sickness | 18 | 2022 | 142 | 2.490 |
Why?
| | Fetal Development | 9 | 2024 | 298 | 2.240 |
Why?
| | Placental Circulation | 10 | 2025 | 71 | 2.240 |
Why?
| | Birth Weight | 23 | 2024 | 522 | 2.060 |
Why?
| | Adaptation, Physiological | 14 | 2026 | 568 | 1.880 |
Why?
| | Vasodilation | 10 | 2022 | 522 | 1.820 |
Why?
| | Arteries | 10 | 2022 | 262 | 1.810 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2023 | 69 | 1.800 |
Why?
| | Oxygen | 17 | 2023 | 998 | 1.700 |
Why?
| | Bolivia | 21 | 2025 | 64 | 1.600 |
Why?
| | Biological Evolution | 6 | 2025 | 473 | 1.460 |
Why?
| | Vasoconstriction | 5 | 2015 | 216 | 1.320 |
Why?
| | Regional Blood Flow | 10 | 2024 | 514 | 1.170 |
Why?
| | Middle Cerebral Artery | 2 | 2024 | 57 | 1.020 |
Why?
| | Female | 104 | 2026 | 80081 | 0.980 |
Why?
| | Nitric Oxide Synthase | 4 | 2019 | 234 | 0.970 |
Why?
| | Myometrium | 2 | 2020 | 38 | 0.960 |
Why?
| | Selection, Genetic | 8 | 2019 | 270 | 0.950 |
Why?
| | Fertility | 2 | 2021 | 175 | 0.860 |
Why?
| | Oxygen Consumption | 15 | 2012 | 721 | 0.850 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 959 | 0.840 |
Why?
| | HELLP Syndrome | 1 | 2023 | 5 | 0.800 |
Why?
| | Hemodynamics | 9 | 2024 | 1127 | 0.750 |
Why?
| | Humans | 110 | 2026 | 147306 | 0.720 |
Why?
| | Vascular Resistance | 7 | 2024 | 372 | 0.710 |
Why?
| | Tibet | 14 | 2021 | 23 | 0.700 |
Why?
| | Pregnancy Complications | 7 | 2026 | 607 | 0.700 |
Why?
| | Adult | 60 | 2025 | 41406 | 0.690 |
Why?
| | Pregnancy, Animal | 4 | 2006 | 51 | 0.680 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2019 | 450 | 0.670 |
Why?
| | Infant, Newborn | 23 | 2024 | 6543 | 0.650 |
Why?
| | Gestational Age | 11 | 2024 | 997 | 0.640 |
Why?
| | Hemoglobins | 8 | 2017 | 386 | 0.640 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.620 |
Why?
| | Exercise | 8 | 2018 | 2219 | 0.590 |
Why?
| | Adrenergic alpha-Antagonists | 4 | 2003 | 34 | 0.590 |
Why?
| | Pregnancy Outcome | 4 | 2019 | 506 | 0.580 |
Why?
| | Fetus | 6 | 2025 | 805 | 0.580 |
Why?
| | Polycythemia | 3 | 2017 | 25 | 0.570 |
Why?
| | Maternal-Fetal Exchange | 4 | 2021 | 171 | 0.560 |
Why?
| | Protein Kinases | 1 | 2020 | 312 | 0.540 |
Why?
| | Maternal Health Services | 1 | 2019 | 101 | 0.510 |
Why?
| | Catecholamines | 8 | 2003 | 88 | 0.490 |
Why?
| | Women's Health | 2 | 2011 | 317 | 0.460 |
Why?
| | Nitric Oxide | 4 | 2020 | 892 | 0.460 |
Why?
| | Menstrual Cycle | 7 | 2003 | 145 | 0.460 |
Why?
| | Infant, Small for Gestational Age | 3 | 2011 | 118 | 0.450 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 307 | 0.420 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 60 | 0.410 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 434 | 0.410 |
Why?
| | Animals | 27 | 2026 | 38417 | 0.410 |
Why?
| | Aromatase | 1 | 2014 | 37 | 0.410 |
Why?
| | Genetics, Population | 6 | 2010 | 226 | 0.390 |
Why?
| | Blood Pressure | 11 | 2020 | 1785 | 0.390 |
Why?
| | Endothelin-1 | 2 | 2020 | 181 | 0.380 |
Why?
| | Polymorphism, Single Nucleotide | 10 | 2019 | 2223 | 0.380 |
Why?
| | Ultrasonography, Doppler | 3 | 2020 | 126 | 0.370 |
Why?
| | Indians, South American | 6 | 2015 | 23 | 0.370 |
Why?
| | PPAR gamma | 3 | 2020 | 182 | 0.370 |
Why?
| | Phenylephrine | 6 | 2020 | 74 | 0.360 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 76 | 0.360 |
Why?
| | Estrogens | 2 | 2014 | 368 | 0.360 |
Why?
| | Respiratory Mechanics | 4 | 2007 | 75 | 0.360 |
Why?
| | Guinea Pigs | 8 | 2006 | 159 | 0.350 |
Why?
| | Angiotensin II | 2 | 2011 | 102 | 0.350 |
Why?
| | Infant, Low Birth Weight | 2 | 2011 | 156 | 0.350 |
Why?
| | Sleep Apnea Syndromes | 1 | 2013 | 98 | 0.340 |
Why?
| | Gene Frequency | 5 | 2014 | 498 | 0.340 |
Why?
| | Enzymes | 1 | 2011 | 60 | 0.340 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2011 | 8 | 0.340 |
Why?
| | Travel | 1 | 2012 | 136 | 0.330 |
Why?
| | Young Adult | 12 | 2024 | 14437 | 0.330 |
Why?
| | Genome, Human | 4 | 2012 | 426 | 0.330 |
Why?
| | Prazosin | 5 | 2003 | 25 | 0.320 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 4 | 0.320 |
Why?
| | Homeostasis | 2 | 2014 | 651 | 0.320 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 15 | 0.320 |
Why?
| | South America | 5 | 2017 | 56 | 0.310 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1122 | 0.310 |
Why?
| | Infant Mortality | 2 | 2021 | 129 | 0.310 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 74 | 0.300 |
Why?
| | Interleukin-1beta | 1 | 2010 | 394 | 0.270 |
Why?
| | Ultrasonography, Prenatal | 3 | 2024 | 295 | 0.270 |
Why?
| | Antioxidants | 1 | 2011 | 550 | 0.270 |
Why?
| | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2011 | 4 | 0.270 |
Why?
| | Mountaineering | 2 | 2005 | 36 | 0.270 |
Why?
| | Heart Rate | 7 | 2015 | 860 | 0.260 |
Why?
| | Case-Control Studies | 6 | 2024 | 3660 | 0.260 |
Why?
| | Chronic Disease | 9 | 2013 | 1845 | 0.250 |
Why?
| | Europe | 4 | 2009 | 426 | 0.240 |
Why?
| | Blood Flow Velocity | 4 | 2011 | 422 | 0.240 |
Why?
| | Oxidative Stress | 1 | 2013 | 1368 | 0.230 |
Why?
| | Vasoconstrictor Agents | 3 | 2020 | 150 | 0.230 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2005 | 49 | 0.230 |
Why?
| | Acetylcholine | 2 | 2020 | 209 | 0.220 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 83 | 0.220 |
Why?
| | Research | 2 | 2005 | 435 | 0.220 |
Why?
| | Fetal Death | 2 | 2003 | 59 | 0.220 |
Why?
| | Cytokines | 2 | 2010 | 2087 | 0.210 |
Why?
| | Umbilical Arteries | 1 | 2024 | 52 | 0.210 |
Why?
| | Embryonic and Fetal Development | 2 | 2003 | 93 | 0.210 |
Why?
| | Placental Insufficiency | 2 | 2023 | 126 | 0.200 |
Why?
| | Epinephrine | 3 | 2001 | 160 | 0.200 |
Why?
| | Mammals | 2 | 2022 | 286 | 0.200 |
Why?
| | Models, Genetic | 2 | 2007 | 536 | 0.200 |
Why?
| | Norepinephrine | 3 | 2001 | 201 | 0.200 |
Why?
| | Chi-Square Distribution | 2 | 2018 | 528 | 0.200 |
Why?
| | Peru | 2 | 2021 | 61 | 0.200 |
Why?
| | Parity | 2 | 2018 | 112 | 0.200 |
Why?
| | Infant | 6 | 2021 | 10195 | 0.200 |
Why?
| | Mice | 8 | 2021 | 18493 | 0.190 |
Why?
| | Interleukin-6 | 2 | 2010 | 784 | 0.190 |
Why?
| | Mining | 1 | 2003 | 36 | 0.190 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.180 |
Why?
| | Silver | 1 | 2003 | 36 | 0.180 |
Why?
| | In Vitro Techniques | 4 | 2011 | 1049 | 0.180 |
Why?
| | Speech Disorders | 1 | 2002 | 29 | 0.180 |
Why?
| | Receptors, Adrenergic, alpha-1 | 2 | 2001 | 45 | 0.180 |
Why?
| | Geography | 3 | 2011 | 187 | 0.180 |
Why?
| | Amino Acids | 3 | 2023 | 519 | 0.180 |
Why?
| | Regression Analysis | 3 | 2018 | 1003 | 0.180 |
Why?
| | Fatty Acids | 1 | 2025 | 461 | 0.180 |
Why?
| | Progesterone | 5 | 2003 | 215 | 0.180 |
Why?
| | Myoglobin | 1 | 2002 | 13 | 0.180 |
Why?
| | Carbohydrate Metabolism | 2 | 2000 | 59 | 0.180 |
Why?
| | Cerebrovascular Circulation | 1 | 2024 | 293 | 0.180 |
Why?
| | Vasodilator Agents | 2 | 2020 | 330 | 0.170 |
Why?
| | Potassium Channels | 2 | 2022 | 148 | 0.170 |
Why?
| | Erythropoiesis | 1 | 2001 | 57 | 0.170 |
Why?
| | Adrenergic alpha-Agonists | 4 | 2003 | 28 | 0.170 |
Why?
| | Motor Skills | 1 | 2002 | 104 | 0.170 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 822 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2021 | 2625 | 0.170 |
Why?
| | Trophoblasts | 2 | 2019 | 219 | 0.170 |
Why?
| | Reproduction | 1 | 2003 | 212 | 0.170 |
Why?
| | Developing Countries | 1 | 2023 | 318 | 0.170 |
Why?
| | Luteal Phase | 5 | 2001 | 51 | 0.160 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2020 | 12 | 0.160 |
Why?
| | Pyrones | 1 | 2020 | 11 | 0.160 |
Why?
| | Ribonucleotides | 1 | 2020 | 26 | 0.160 |
Why?
| | Signal Transduction | 3 | 2024 | 5272 | 0.160 |
Why?
| | Glycolysis | 2 | 2021 | 341 | 0.160 |
Why?
| | Muscle Relaxation | 1 | 2000 | 28 | 0.160 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2000 | 35 | 0.160 |
Why?
| | Genotype | 4 | 2014 | 1875 | 0.150 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 138 | 0.150 |
Why?
| | Biphenyl Compounds | 1 | 2020 | 67 | 0.150 |
Why?
| | Male | 26 | 2019 | 73954 | 0.150 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1977 | 0.150 |
Why?
| | Genetic Markers | 3 | 2012 | 338 | 0.150 |
Why?
| | Reproductive Health | 1 | 2021 | 94 | 0.150 |
Why?
| | Thiophenes | 1 | 2020 | 117 | 0.150 |
Why?
| | Arterial Pressure | 2 | 2017 | 134 | 0.150 |
Why?
| | Respiratory Function Tests | 3 | 2013 | 545 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 252 | 0.150 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 2 | 2017 | 21 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 197 | 0.150 |
Why?
| | Risk Factors | 5 | 2019 | 11017 | 0.140 |
Why?
| | Erythropoietin | 2 | 2017 | 100 | 0.140 |
Why?
| | Blood Volume | 4 | 2007 | 65 | 0.140 |
Why?
| | Biological Transport | 3 | 2019 | 425 | 0.140 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 6042 | 0.140 |
Why?
| | Follicular Phase | 5 | 2001 | 41 | 0.140 |
Why?
| | Blood Gas Analysis | 3 | 2007 | 82 | 0.140 |
Why?
| | Glyburide | 1 | 1998 | 31 | 0.140 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 43 | 0.140 |
Why?
| | Analysis of Variance | 3 | 2011 | 1302 | 0.140 |
Why?
| | Maternal Age | 1 | 2018 | 129 | 0.140 |
Why?
| | Estradiol | 5 | 2003 | 515 | 0.140 |
Why?
| | Body Weights and Measures | 2 | 2015 | 37 | 0.140 |
Why?
| | Intraocular Pressure | 1 | 2000 | 332 | 0.130 |
Why?
| | Delivery, Obstetric | 2 | 2011 | 164 | 0.130 |
Why?
| | Health Promotion | 1 | 2005 | 792 | 0.130 |
Why?
| | DNA | 2 | 2006 | 1444 | 0.130 |
Why?
| | Sudden Infant Death | 1 | 1998 | 40 | 0.130 |
Why?
| | Respiration | 3 | 2005 | 208 | 0.130 |
Why?
| | Ethiopia | 1 | 2017 | 44 | 0.130 |
Why?
| | Phenotype | 3 | 2025 | 3216 | 0.130 |
Why?
| | Cohort Studies | 4 | 2020 | 6099 | 0.130 |
Why?
| | Models, Biological | 4 | 2015 | 1772 | 0.130 |
Why?
| | Glucose | 2 | 2023 | 1051 | 0.130 |
Why?
| | Physical Endurance | 2 | 2001 | 279 | 0.130 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 26 | 0.120 |
Why?
| | Vascular Diseases | 2 | 2017 | 252 | 0.120 |
Why?
| | Ovariectomy | 1 | 1997 | 166 | 0.120 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 21 | 0.120 |
Why?
| | Linear Models | 2 | 2014 | 852 | 0.120 |
Why?
| | Pulmonary Gas Exchange | 2 | 2015 | 117 | 0.120 |
Why?
| | Cardiovascular System | 1 | 2017 | 139 | 0.120 |
Why?
| | Time Factors | 8 | 2011 | 7173 | 0.120 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 6011 | 0.110 |
Why?
| | Pregnancy Complications, Cardiovascular | 3 | 2007 | 85 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2023 | 552 | 0.110 |
Why?
| | Polymorphism, Genetic | 2 | 2012 | 615 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1550 | 0.110 |
Why?
| | Electrocardiography | 1 | 1998 | 675 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 538 | 0.110 |
Why?
| | Adolescent | 5 | 2019 | 22826 | 0.110 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 203 | 0.110 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 43 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2954 | 0.100 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 48 | 0.100 |
Why?
| | Double-Blind Method | 4 | 2003 | 2080 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2974 | 0.100 |
Why?
| | Body Height | 2 | 2013 | 205 | 0.100 |
Why?
| | Body Weight | 3 | 2007 | 976 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2021 | 663 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2022 | 17561 | 0.100 |
Why?
| | Sex Characteristics | 5 | 2001 | 799 | 0.100 |
Why?
| | Atmosphere Exposure Chambers | 2 | 2002 | 6 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 143 | 0.090 |
Why?
| | Hypertension | 3 | 2015 | 1280 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2014 | 374 | 0.090 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2012 | 49 | 0.090 |
Why?
| | Pulmonary Artery | 2 | 2015 | 1132 | 0.090 |
Why?
| | Pregnancy Trimesters | 1 | 2012 | 20 | 0.090 |
Why?
| | Optic Atrophy, Hereditary, Leber | 1 | 2012 | 9 | 0.090 |
Why?
| | Indomethacin | 1 | 2012 | 77 | 0.090 |
Why?
| | NADH Dehydrogenase | 1 | 2012 | 20 | 0.090 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2012 | 82 | 0.090 |
Why?
| | Reference Values | 4 | 2003 | 800 | 0.090 |
Why?
| | Lactic Acid | 3 | 2023 | 295 | 0.090 |
Why?
| | Brain | 1 | 2024 | 3009 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 318 | 0.090 |
Why?
| | Age Factors | 2 | 2011 | 3372 | 0.090 |
Why?
| | Polysomnography | 1 | 2013 | 240 | 0.090 |
Why?
| | Apgar Score | 1 | 2011 | 22 | 0.080 |
Why?
| | Colorado | 5 | 2019 | 4591 | 0.080 |
Why?
| | Prevalence | 1 | 2018 | 2889 | 0.080 |
Why?
| | Population Dynamics | 1 | 2012 | 143 | 0.080 |
Why?
| | Atmospheric Pressure | 2 | 2001 | 26 | 0.080 |
Why?
| | Potassium Chloride | 1 | 2011 | 40 | 0.080 |
Why?
| | Nitroarginine | 2 | 2002 | 57 | 0.080 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 31 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 456 | 0.080 |
Why?
| | Iliac Artery | 1 | 2011 | 55 | 0.080 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 212 | 0.080 |
Why?
| | Live Birth | 1 | 2011 | 81 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2011 | 330 | 0.080 |
Why?
| | Stillbirth | 1 | 2011 | 83 | 0.080 |
Why?
| | DNA Methylation | 1 | 2015 | 722 | 0.080 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 36 | 0.080 |
Why?
| | Child Development | 1 | 2015 | 484 | 0.080 |
Why?
| | Sympathetic Nervous System | 2 | 2003 | 181 | 0.080 |
Why?
| | Alleles | 3 | 2012 | 909 | 0.080 |
Why?
| | Ultrasonography | 1 | 2014 | 795 | 0.080 |
Why?
| | Anthropology, Physical | 1 | 2009 | 24 | 0.080 |
Why?
| | Haplotypes | 3 | 2017 | 509 | 0.080 |
Why?
| | Interleukin-4 | 1 | 2010 | 207 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4605 | 0.080 |
Why?
| | Middle Aged | 5 | 2019 | 36821 | 0.080 |
Why?
| | Mesenteric Arteries | 2 | 2000 | 17 | 0.070 |
Why?
| | Renal Circulation | 3 | 1998 | 75 | 0.070 |
Why?
| | Sheep | 2 | 2023 | 879 | 0.070 |
Why?
| | Genomics | 2 | 2023 | 839 | 0.070 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 253 | 0.070 |
Why?
| | Databases, Genetic | 1 | 2010 | 240 | 0.070 |
Why?
| | Pedigree | 1 | 2010 | 522 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 787 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 848 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 311 | 0.070 |
Why?
| | Ovary | 2 | 2018 | 236 | 0.070 |
Why?
| | Basal Metabolism | 3 | 2003 | 59 | 0.070 |
Why?
| | Exercise Test | 3 | 2001 | 636 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1456 | 0.070 |
Why?
| | Indians, North American | 2 | 2009 | 567 | 0.060 |
Why?
| | Lung | 1 | 2021 | 4141 | 0.060 |
Why?
| | Heart Rate, Fetal | 1 | 2007 | 31 | 0.060 |
Why?
| | Biometry | 1 | 2007 | 66 | 0.060 |
Why?
| | Head | 1 | 2008 | 127 | 0.060 |
Why?
| | Urban Health | 1 | 2007 | 96 | 0.060 |
Why?
| | Premature Birth | 1 | 2011 | 390 | 0.060 |
Why?
| | Aorta, Thoracic | 2 | 2000 | 288 | 0.060 |
Why?
| | Prospective Studies | 3 | 2022 | 8166 | 0.060 |
Why?
| | Femur | 1 | 2008 | 261 | 0.060 |
Why?
| | Health Status | 1 | 2011 | 839 | 0.060 |
Why?
| | Phylogeny | 2 | 2010 | 924 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 512 | 0.060 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2007 | 107 | 0.060 |
Why?
| | Serum | 1 | 2006 | 58 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2006 | 69 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1225 | 0.060 |
Why?
| | Hyperplasia | 1 | 2006 | 177 | 0.060 |
Why?
| | Carnitine | 1 | 2025 | 91 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 321 | 0.050 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2001 | 18 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2458 | 0.050 |
Why?
| | History, 21st Century | 1 | 2005 | 227 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2019 | 3029 | 0.050 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 185 | 0.050 |
Why?
| | History, 20th Century | 1 | 2005 | 333 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 6164 | 0.050 |
Why?
| | Mental Health | 1 | 2011 | 813 | 0.050 |
Why?
| | Plasma Volume | 1 | 2003 | 20 | 0.050 |
Why?
| | Cardiac Output | 3 | 1998 | 179 | 0.050 |
Why?
| | Child | 4 | 2015 | 22980 | 0.050 |
Why?
| | Pyruvates | 1 | 2023 | 23 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1794 | 0.050 |
Why?
| | Embryo Implantation | 1 | 2003 | 34 | 0.050 |
Why?
| | History, 17th Century | 1 | 2003 | 14 | 0.050 |
Why?
| | Meclofenamic Acid | 1 | 2002 | 9 | 0.050 |
Why?
| | Acute Disease | 2 | 2005 | 1049 | 0.050 |
Why?
| | Lower Extremity | 1 | 2007 | 452 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 129 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 300 | 0.050 |
Why?
| | Primary Prevention | 1 | 2005 | 228 | 0.050 |
Why?
| | Sound Spectrography | 1 | 2002 | 15 | 0.050 |
Why?
| | Glutamine | 1 | 2023 | 110 | 0.050 |
Why?
| | Speech Acoustics | 1 | 2002 | 11 | 0.050 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 873 | 0.050 |
Why?
| | Ischemia | 1 | 2006 | 424 | 0.050 |
Why?
| | Serine | 1 | 2023 | 143 | 0.050 |
Why?
| | Locomotion | 1 | 2003 | 101 | 0.040 |
Why?
| | Muscle Fatigue | 2 | 2001 | 98 | 0.040 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 78 | 0.040 |
Why?
| | Partial Pressure | 1 | 2001 | 30 | 0.040 |
Why?
| | Glycine | 1 | 2023 | 186 | 0.040 |
Why?
| | Species Specificity | 1 | 2003 | 547 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2001 | 29 | 0.040 |
Why?
| | Health Education | 1 | 2005 | 346 | 0.040 |
Why?
| | Cesarean Section | 1 | 2023 | 230 | 0.040 |
Why?
| | Plethysmography | 1 | 2001 | 104 | 0.040 |
Why?
| | Veins | 1 | 2001 | 69 | 0.040 |
Why?
| | Pyruvic Acid | 1 | 2021 | 51 | 0.040 |
Why?
| | C-Peptide | 2 | 2001 | 191 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2003 | 347 | 0.040 |
Why?
| | Blood Glucose | 3 | 2001 | 2359 | 0.040 |
Why?
| | Forearm | 1 | 2001 | 141 | 0.040 |
Why?
| | Ventricular Pressure | 1 | 2021 | 52 | 0.040 |
Why?
| | Hyperbaric Oxygenation | 1 | 2021 | 39 | 0.040 |
Why?
| | Arginine | 1 | 2002 | 265 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Insulin | 3 | 2001 | 2526 | 0.040 |
Why?
| | Exons | 1 | 2002 | 365 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 995 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2002 | 494 | 0.040 |
Why?
| | Asia | 1 | 2000 | 70 | 0.040 |
Why?
| | Posture | 1 | 2001 | 197 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3784 | 0.040 |
Why?
| | Tonometry, Ocular | 1 | 2000 | 104 | 0.040 |
Why?
| | Bromodeoxyuridine | 1 | 2000 | 77 | 0.040 |
Why?
| | Muscle Contraction | 2 | 2001 | 429 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2001 | 1798 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 500 | 0.040 |
Why?
| | Fetal Weight | 1 | 2000 | 53 | 0.040 |
Why?
| | Paleontology | 1 | 2000 | 19 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2002 | 617 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 26 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2001 | 228 | 0.040 |
Why?
| | Endothelium | 1 | 2000 | 119 | 0.040 |
Why?
| | Archaeology | 1 | 2000 | 36 | 0.040 |
Why?
| | Geographic Mapping | 1 | 2019 | 26 | 0.040 |
Why?
| | North America | 1 | 2000 | 307 | 0.040 |
Why?
| | Organ Size | 1 | 2000 | 465 | 0.040 |
Why?
| | Thiazolidinediones | 1 | 2020 | 143 | 0.040 |
Why?
| | Litter Size | 1 | 1998 | 18 | 0.030 |
Why?
| | Cell Division | 1 | 2000 | 758 | 0.030 |
Why?
| | Potassium Channel Blockers | 1 | 1998 | 47 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1481 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 300 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2006 | 4170 | 0.030 |
Why?
| | Hormones | 1 | 1998 | 136 | 0.030 |
Why?
| | Carotid Sinus | 1 | 1997 | 2 | 0.030 |
Why?
| | Adrenal Glands | 1 | 1998 | 77 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 430 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2002 | 586 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 234 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2030 | 0.030 |
Why?
| | Glucagon | 1 | 2018 | 114 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1998 | 152 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1997 | 50 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 2017 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1998 | 430 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 361 | 0.030 |
Why?
| | Glomerular Filtration Rate | 2 | 1998 | 765 | 0.030 |
Why?
| | Cats | 1 | 1997 | 241 | 0.030 |
Why?
| | Genome-Wide Association Study | 2 | 2017 | 1496 | 0.030 |
Why?
| | China | 1 | 1997 | 278 | 0.030 |
Why?
| | Ferritins | 1 | 2017 | 70 | 0.030 |
Why?
| | Energy Intake | 1 | 2000 | 514 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 633 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1721 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 12017 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2020 | 1730 | 0.030 |
Why?
| | California | 1 | 2017 | 477 | 0.030 |
Why?
| | Renin-Angiotensin System | 2 | 2010 | 80 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 849 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 2015 | 112 | 0.030 |
Why?
| | Anesthesia | 1 | 1997 | 257 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2000 | 937 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 590 | 0.020 |
Why?
| | Latin America | 1 | 2012 | 96 | 0.020 |
Why?
| | Aged | 2 | 2017 | 26516 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 303 | 0.020 |
Why?
| | Globins | 1 | 2010 | 21 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2010 | 27 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 708 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1342 | 0.020 |
Why?
| | Thumb | 2 | 2001 | 38 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 190 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 780 | 0.020 |
Why?
| | Hydrocortisone | 2 | 2002 | 300 | 0.020 |
Why?
| | Cyclic GMP | 2 | 1998 | 90 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4384 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2886 | 0.020 |
Why?
| | Indians, Central American | 1 | 2007 | 6 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 45 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5478 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1992 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2007 | 273 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4354 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 751 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8432 | 0.010 |
Why?
| | International Cooperation | 1 | 2005 | 198 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3565 | 0.010 |
Why?
| | Heart Failure | 1 | 2017 | 2334 | 0.010 |
Why?
| | Genetic Testing | 1 | 2007 | 493 | 0.010 |
Why?
| | Tilt-Table Test | 1 | 2001 | 8 | 0.010 |
Why?
| | Placebos | 1 | 2001 | 193 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2001 | 147 | 0.010 |
Why?
| | Societies, Medical | 1 | 2005 | 914 | 0.010 |
Why?
| | Transducers, Pressure | 1 | 1999 | 12 | 0.010 |
Why?
| | Water-Electrolyte Balance | 1 | 2000 | 37 | 0.010 |
Why?
| | Fasting | 1 | 2001 | 280 | 0.010 |
Why?
| | Nitrogen | 1 | 2000 | 125 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 277 | 0.010 |
Why?
| | Electrolytes | 1 | 1998 | 54 | 0.010 |
Why?
| | Pregnancy Trimester, First | 1 | 1998 | 139 | 0.010 |
Why?
| | Renin | 1 | 1997 | 33 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 55 | 0.010 |
Why?
| | Aldosterone | 1 | 1997 | 42 | 0.010 |
Why?
| | Bicarbonates | 1 | 1997 | 45 | 0.010 |
Why?
| | Nitrites | 1 | 1997 | 88 | 0.010 |
Why?
| | Nitrates | 1 | 1997 | 97 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1997 | 208 | 0.010 |
Why?
| | Chlorides | 1 | 1997 | 138 | 0.010 |
Why?
| | Sodium | 1 | 1997 | 198 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2000 | 1077 | 0.010 |
Why?
| | Body Composition | 1 | 2000 | 694 | 0.010 |
Why?
| | Poverty | 1 | 1999 | 533 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2001 | 1253 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|